Garetosmab
| Clinical data | |
|---|---|
| Other names | REGN-2477 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Garetosmab is a fully human, experimental monoclonal antibody against activin-A. It has been tried in patients with fibrodysplasia ossificans progressiva and the manufacturer, Regeneron, also plans to test it in patients with obesity as an add-on to existing weight loss drugs such as GLP-1 agonists, in order to help patients maintain muscle mass during weight loss.[1][2][3]
References[edit]
- ^ "In obesity, Regeneron wants to fill gaps. But for cell therapy? George Yancopoulos wants to try something new". fiercebiotech.com. Retrieved 6 March 2024.
- ^ Di Rocco, Maja; Forleo-Neto, Eduardo; Pignolo, Robert J.; Keen, Richard; Orcel, Philippe; Funck-Brentano, Thomas; Roux, Christian; Kolta, Sami; Madeo, Annalisa; Bubbear, Judith S.; Tabarkiewicz, Jacek; Szczepanek, Małgorzata; Bachiller-Corral, Javier; Cheung, Angela M.; Dahir, Kathryn M.; Botman, Esmée; Raijmakers, Pieter G.; Al Mukaddam, Mona; Tile, Lianne; Portal-Celhay, Cynthia; Sarkar, Neena; Hou, Peijie; Musser, Bret J.; Boyapati, Anita; Mohammadi, Kusha; Mellis, Scott J.; Rankin, Andrew J.; Economides, Aris N.; Trotter, Dinko Gonzalez; Herman, Gary A.; O’Meara, Sarah J.; DelGizzi, Richard; Weinreich, David M.; Yancopoulos, George D.; Eekhoff, E. Marelise W.; Kaplan, Frederick S. (October 2023). "Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial". Nature Medicine. 29 (10): 2615–2624. doi:10.1038/s41591-023-02561-8. PMC 10579054. PMID 37770652.
- ^ Wang, Yuhuan; Nguyen, Jenny-Hoa; de Ruiter, Ruben R D; Mendell, Jeanne; Srinivasan, Dushyanth; Davis, John D; Eekhoff, Marelise W (5 October 2023). "THU467 Pharmacokinetics And Pharmacodynamics Of Garetosmab In Patients With Fibrodysplasia Ossificans Progressiva". Journal of the Endocrine Society. 7 (Supplement_1): bvad114.428. doi:10.1210/jendso/bvad114.428. PMC 10554036.